Status:
COMPLETED
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
Lead Sponsor:
GlobeImmune
Conditions:
Pancreas Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients. Patients will be monitored for recurrence as well as safety, and ...
Eligibility Criteria
Inclusion
- (A few general items required)
- Patients with non-metastatic pancreas cancer post-resection that have a product-related ras mutation
- \>18 years of age
- Negative skin test for hypersensitivity to Saccharomyces cerevisiae
Exclusion
- Metastatic pancreas cancer patients post-resection
- Patients with no product-related ras mutation.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT00300950
Start Date
January 1 2006
End Date
February 1 2015
Last Update
April 6 2015
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Tower Cancer Research Foundation
Beverly Hills, California, United States, 90211
3
University of California San Diego
La Jolla, California, United States, 92093
4
UCLA Medical Center
Los Angeles, California, United States, 90095